CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market Share Analysis, 2017
3.4. Clinical trials
3.5. Patent analysis, 2014-2018

3.5.1. Patent analysis, by year (2014-2018)
3.5.2. Patent analysis, by country

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of chronic diseases
3.6.1.2. Rise in geriatric population and improvement in healthcare infrastructure
3.6.1.3. Increase in strategic acquisitions and collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Stringent regulatory scenario

3.6.3. Opportunity

3.6.3.1. Increase in purchasing power of emerging economics

CHAPTER 4: BIOPHARMACEUTICALS MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Monoclonal Antibodies

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Interferons

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Insulin

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Growth and coagulation factors

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Erythropoietin

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Vaccines

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Hormones

4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

4.9. Other

4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

CHAPTER 5: BIOPHARMACEUTICALS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Blood Disorders

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Metabolic Diseases

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Infectious Diseases

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Cardiovascular Diseases

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

5.7. Neurological Diseases

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country

5.8. Immunology

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country

5.9. Other Applications

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by country

CHAPTER 6: BIOPHARMACEUTICALS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America Biopharmaceuticals market size and forecast, by country

6.2.2.1. U.S. market size and forecast

6.2.2.1.1. U.S. Biopharmaceuticals market, by type
6.2.2.1.2. U.S. Biopharmaceuticals market, by application

6.2.2.2. Canada market size and forecast

6.2.2.2.1. Canada Biopharmaceuticals market, by type
6.2.2.2.2. Canada Biopharmaceuticals market, by application

6.2.2.3. Mexico market size and forecast

6.2.2.3.1. Mexico Biopharmaceuticals market, by type
6.2.2.3.2. Mexico Biopharmaceuticals market, by application

6.2.3. North America Biopharmaceuticals market size and forecast, by type
6.2.4. North America Biopharmaceuticals market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe Biopharmaceuticals market size and forecast, by country

6.3.2.1. Germany market size and forecast

6.3.2.1.1. Germany. Biopharmaceuticals market, by type
6.3.2.1.2. Germany Biopharmaceuticals market, by application

6.3.2.2. France market size and forecast

6.3.2.2.1. France Biopharmaceuticals market, by type
6.3.2.2.2. France Biopharmaceuticals market, by application

6.3.2.3. UK market size and forecast

6.3.2.3.1. UK Biopharmaceuticals market, by type
6.3.2.3.2. UK Biopharmaceuticals market, by application

6.3.2.4. Italy market size and forecast

6.3.2.4.1. Italy Biopharmaceuticals market, by type
6.3.2.4.2. Italy Biopharmaceuticals market, by application

6.3.2.5. Spain market size and forecast

6.3.2.5.1. Spain. Biopharmaceuticals market, by type
6.3.2.5.2. Spain Biopharmaceuticals market, by application

6.3.2.6. Rest of Europe market size and forecast

6.3.2.6.1. Rest of Europe Biopharmaceuticals market, by type
6.3.2.6.2. Rest of Europe Biopharmaceuticals market, by application

6.3.3. Europe Biopharmaceuticals market size and forecast, by type
6.3.4. Europe Biopharmaceuticals market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific Biopharmaceuticals market size and forecast, by country

6.4.2.1. Japan market size and forecast

6.4.2.1.1. Japan Biopharmaceuticals market, by type
6.4.2.1.2. Japan Biopharmaceuticals market, by application

6.4.2.2. China market size and forecast

6.4.2.2.1. China Biopharmaceuticals market, by type
6.4.2.2.2. China Biopharmaceuticals market, by application

6.4.2.3. India market size and forecast

6.4.2.3.1. India Biopharmaceuticals market, by type
6.4.2.3.2. India Biopharmaceuticals market, by application

6.4.2.4. Australia market size and forecast

6.4.2.4.1. Australia Biopharmaceuticals market, by type
6.4.2.4.2. Australia Biopharmaceuticals market, by application

6.4.2.5. South Korea market size and forecast

6.4.2.5.1. South Korea Biopharmaceuticals market, by type
6.4.2.5.2. South Korea Biopharmaceuticals market, by application

6.4.2.6. Rest of Asia-Pacific market size and forecast

6.4.2.6.1. Rest of Asia-Pacific Biopharmaceuticals market, by type
6.4.2.6.2. Rest of Asia-Pacific Biopharmaceuticals market, by application

6.4.3. Asia-Pacific Biopharmaceuticals market size and forecast, by type
6.4.4. Asia-Pacific Biopharmaceuticals market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA Biopharmaceuticals market size and forecast, by country

6.5.2.1. Brazil market size and forecast

6.5.2.1.1. Brazil Biopharmaceuticals market, by type
6.5.2.1.2. Brazil Biopharmaceuticals market, by application

6.5.2.2. Saudi Arabia market size and forecast

6.5.2.2.1. Saudi Arabia. Biopharmaceuticals market, by type
6.5.2.2.2. Saudi Arabia Biopharmaceuticals market, by application

6.5.2.3. South Africa market size and forecast

6.5.2.3.1. South Africa Biopharmaceuticals market, by type
6.5.2.3.2. South Africa Biopharmaceuticals market, by application

6.5.2.4. Rest of LAMEA market size and forecast

6.5.2.4.1. Rest of LAMEA Biopharmaceuticals market, by type
6.5.2.4.2. Rest of LAMEA Biopharmaceuticals market, by application

6.5.3. LAMEA Biopharmaceuticals market size and forecast, by type
6.5.4. LAMEA Biopharmaceuticals market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

7.1. Abbott Laboratories

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. Amgen Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. Biogen Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Eli Lilly and Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. Hoffmann-La Roche Ltd.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Johnson & Johnson

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Merck & Co., Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Novo Nordisk A/S

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Pfizer Inc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Sanofi

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments